Balyasny Asset Management LLC Immunovant, Inc. Transaction History

Balyasny Asset Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$31.31 - $44.19 $306,305 - $432,310	9,783 New	9,783 $412,000
Q2 2023 Aug 14, 2023	BUY	$14.2 - $23.75 $3.63 Million - $6.07 Million	255,677 New	255,677 $4.85 Million
Q4 2022 Feb 14, 2023	BUY	$6.59 - $17.75 $1.46 Million - $3.95 Million	222,272 Added 144.8%	375,775 $6.67 Million
Q3 2022 Nov 14, 2022	BUY	$3.93 - $6.37 $603,266 - $977,814	153,503 New	153,503 $857,000
Q2 2022 Aug 15, 2022	SELL	$3.38 - $5.65 $49,402 - $82,580	-14,616 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$5.06 - $8.77 $73,956 - $128,182	14,616 New	14,616 $81,000
Q1 2021 May 17, 2021	SELL	$13.08 - $49.6 $784,459 - $2.97 Million	-59,974 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$36.36 - $52.71 $2.18 Million - $3.16 Million	59,974 New	59,974 $2.77 Million

212

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.